Adtalem vs Stride

This page compares Adtalem and Stride, examining their business models, financial performance, and market context in clear, neutral terms. It presents factual context to help readers understand each company’s position relative to one another. Educational content, not financial advice.

Comparison Snapshot

Key Financial Metrics

ATGE

Metric

LRN

$4.13B

Market Cap

$3.04B

39.81%

Potential Profit

71.21%

Strong Buy

Analyst Rating

Buy

Investment Analysis

Adtalem

ATGE

Pros

Adtalem showed strong Q3 2025 results with revenue up 12.1% and a 28% increase in EPS, demonstrating robust growth and solid fundamentals.
The company generated significant free cash flow of $57 million annually with an impressive 78.5% yearly growth in cash flows, highlighting operational efficiency.
Adtalem operates diversified segments including Chamberlain, Walden, and Medical and Veterinary, with strong market positioning in healthcare education.

Considerations

Recent stock volatility has been high, with a 35% price drop over one month, reflecting investor nervousness around sector-wide volatility and competitive pressures.
Despite strong fundamentals, the stock’s 12-month price target suggests a modest downside of around 5.4%, indicating potential valuation concerns.
The company’s profitability, while improved, still reflects modest margins such as a 10% gross margin, pointing to limited pricing power in a competitive education market.

Stride

LRN

Pros

Stride focuses on digital K-12 education, positioning itself in a growing market segment with innovation initiatives like the 2026 Innovation Challenge.
The company has attracted bottom-line support reflected by some buy-side analyst positive ratings and recent share price rebounds.
Stride offers a platform-based operating model which, if successfully upgraded, could deliver scalable growth and operational leverage.

Considerations

Stride’s recent platform upgrade failed, triggering a significant 49% stock price plunge and a related legal probe, increasing execution risk.
Analysts have lowered price targets recently amid concerns about platform reliability and competitive dynamics in the crowded digital education market.
The company faces intense competition in the digital education sector, which could pressure margins and growth sustainability in the near term.

About The Companies

Adtalem (ATGE)

Adtalem Global Education is a leading provider of professional education, primarily focused on the healthcare sector in the United States. The company operates through three distinct segments: Chamberlain University, Walden University, and its Medical and Veterinary schools. Chamberlain is a major player in nursing and health professions education. Walden offers a broad range of online degree programmes in areas like education, business, and social sciences. The Medical and Veterinary segment includes well-known institutions like Ross University School of Medicine and Ross University School of Veterinary Medicine. By offering a diverse portfolio of degree programmes, Adtalem aims to equip students for careers in high-demand fields. This business model positions the company to tap into the growing need for qualified professionals, though its performance can be influenced by regulatory changes and shifts in student enrolment trends.

Stride (LRN)

Stride Inc (ticker: LRN) is a US-based education company that provides online K–12 programmes, supplemental curriculum, and adult learning solutions through a mix of virtual schools, software platforms and services. Revenue is driven by student enrolment in state-funded virtual schools, subscription licences for curriculum and learning tools, and ancillary services. Investors should note Stride’s exposure to public funding rules, state-level regulation and enrolment trends, which can materially affect top-line stability. The company has pursued product diversification and technology investments to grow beyond traditional virtual schools, but competition from other edtech providers and post-pandemic shifts in schooling models create execution risk. Financial performance can be cyclical with policy changes and seasonal enrolment; profitability depends on scale and cost control. This summary is educational and not investment advice — returns are not guaranteed and share prices can fall as well as rise. Consider suitability and consult a qualified adviser for personalised guidance.

Which Baskets Do They Appear In?

No baskets available in this category

Which Baskets Do They Appear In?

No baskets available in this category

Buy ATGE or LRN in Nemo

🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Comparisons

Adtalem vs Perdoceo Education

Adtalem vs Gaotu

Adtalem vs Gaotu: A stock comparison overview

Adtalem vs Afya

Adtalem vs Afya: Stock comparison

Adtalem vs Stride

Comparison Snapshot

Investment Analysis

Adtalem

Pros

Considerations

Stride

Pros

Considerations

About The Companies

Which Baskets Do They Appear In?

Which Baskets Do They Appear In?

Buy ATGE or LRN in Nemo

Zero Commission

Trusted & Regulated

6% Interest on Cash

Discover More Comparisons

Adtalem vs Perdoceo Education

Adtalem vs Gaotu

Adtalem vs Afya

Frequently asked questions

What is the main purpose of comparing Adtalem and Stride on this page?

How should I read ‘pros and cons’ in this comparison?

What do ‘diversified segments’ mean for Adtalem’s business structure?

What does a high level of free cash flow indicate for Adtalem relative to Stride?

How should I interpret a significant stock price drop versus strong quarterly results?

What role do target prices play in evaluating these stocks?

How do market dynamics in education affect both companies?

What does ‘platform upgrade’ imply for Stride’s growth prospects?

What should a reader take away about comparing these two stocks?

Educational disclaimer: is this page providing buy or sell recommendations?

Comparison Snapshot

About The Companies